Valuation: Hyloris Pharmaceuticals SA

Capitalization 164M 189M 155M 140M 260M 16.38B 293M 1.83B 700M 7.51B 710M 695M 27.59B P/E ratio 2025 *
-7.92x
P/E ratio 2026 * -11.1x
Enterprise value 171M 198M 161M 147M 271M 17.11B 306M 1.91B 732M 7.84B 741M 726M 28.82B EV / Sales 2025 *
21.7x
EV / Sales 2026 * 5x
Free-Float
43.38%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.34%
1 week+1.03%
Current month-0.68%
1 month+3.17%
3 months-13.06%
6 months+10.57%
Current year-10.40%
More quotes
1 week 5.54
Extreme 5.54
5.92
1 month 5.54
Extreme 5.54
6.3
Current year 4.42
Extreme 4.42
7.2
1 year 2.89
Extreme 2.89
11.7
3 years 2.89
Extreme 2.89
15.16
5 years 2.89
Extreme 2.89
19.1
10 years 2.89
Extreme 2.89
19.1
More quotes
Manager TitleAgeSince
Chief Executive Officer 51 -
Chief Executive Officer 49 2011-12-31
Director of Finance/CFO - 2024-12-08
Director TitleAgeSince
Director/Board Member 49 2020-11-29
Director/Board Member 51 2011-12-31
Chairman 63 2019-09-30
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.34%+1.03%-49.91%-59.59% 189M
-2.84%-6.91%-13.71%+156.52% 685B
-0.62%-4.65%+0.70%-13.42% 360B
-0.10%-3.02%+8.75%+29.16% 327B
-2.58%-7.83%-51.84%+25.00% 326B
-0.27%-3.86%+2.57%-13.95% 255B
-0.34%-2.34%+0.96%+20.36% 228B
-1.52%-5.41%-16.68%+2.61% 217B
-0.29%-3.24%-39.52%-10.19% 199B
-0.10%-2.00%-6.11%+21.36% 156B
Average -0.90%-3.65%-16.48%+15.78% 275.22B
Weighted average by Cap. -1.31%-4.71%-12.62%+44.68%
See all sector performances

Financials

2025 *2026 *
Net sales 7.9M 9.11M 7.44M 6.76M 12.51M 789M 14.09M 88.12M 33.72M 361M 34.17M 33.45M 1.33B 33.3M 38.39M 31.37M 28.5M 52.73M 3.32B 59.41M 371M 142M 1.52B 144M 141M 5.6B
Net income -23.4M -26.98M -22.04M -20.03M -37.05M -2.34B -41.75M -261M -99.89M -1.07B -101M -99.07M -3.93B -18.95M -21.85M -17.85M -16.22M -30.01M -1.89B -33.81M -211M -80.89M -867M -81.98M -80.23M -3.19B
Net Debt 7.3M 8.42M 6.88M 6.25M 11.56M 729M 13.02M 81.43M 31.16M 334M 31.58M 30.91M 1.23B 2.5M 2.88M 2.35M 2.14M 3.96M 250M 4.46M 27.89M 10.67M 114M 10.81M 10.58M 420M
More financial data * Estimated data
Logo Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.
Employees
49
More about the company
Date Price Change Volume
25-06-20 5.860 -0.34% 2,771
25-06-19 5.880 +0.34% 2,119
25-06-18 5.860 -0.68% 12,413
25-06-17 5.900 0.00% 763
25-06-16 5.900 +1.72% 3,650

Real-time Euronext Bruxelles, June 20, 2025 at 11:35 am EDT

More quotes
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
5.860EUR
Average target price
12.50EUR
Spread / Average Target
+113.31%
Consensus

Annual profits - Rate of surprise